These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16827161)

  • 1. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
    Radujkovic A; Topaly J; Fruehauf S; Zeller WJ
    Anticancer Res; 2006; 26(3A):2169-77. PubMed ID: 16827161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
    Radujkovic A; Schad M; Topaly J; Veldwijk MR; Laufs S; Schultheis BS; Jauch A; Melo JV; Fruehauf S; Zeller WJ
    Leukemia; 2005 Jul; 19(7):1198-206. PubMed ID: 15902298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
    Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
    Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
    Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
    Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM; Kelly L; Onnis V; Campiani G; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):288-97. PubMed ID: 17202400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
    Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
    Morotti A; Cilloni D; Messa F; Arruga F; Defilippi I; Carturan S; Catalano R; Rosso V; Chiarenza A; Pilatrino C; Guerrasio A; Taulli R; Bracco E; Pautasso M; Baraban D; Gottardi E; Saglio G
    Cancer; 2006 Mar; 106(5):1188-96. PubMed ID: 16444746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
    Desplat V; Belloc F; Lagarde V; Boyer C; Melo JV; Reiffers J; Praloran V; Mahon FX
    Cancer; 2005 Jan; 103(1):102-10. PubMed ID: 15558795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.
    Kawano T; Horiguchi-Yamada J; Iwase S; Akiyama M; Furukawa Y; Kan Y; Yamada H
    Anticancer Res; 2004; 24(5A):2705-12. PubMed ID: 15517875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
    Giallongo C; La Cava P; Tibullo D; Parrinello N; Barbagallo I; Del Fabro V; Stagno F; Conticello C; Romano A; Chiarenza A; Palumbo GA; Di Raimondo F
    Eur J Haematol; 2011 Mar; 86(3):216-25. PubMed ID: 21198861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.